Ciprofibrate

證據等級: L5

預測適應症: 10 個

Using this as a direct content-generation task against the given template — no codebase skill matches “write a repurposing report from a supplied evidence pack,” so I’ll produce the report following the v5 prompt’s structure exactly, drawing only on data present in the JSON (no fabricated licences/history).

A few data-handling notes before the report:

taiwan_regulatory.licenses is empty and original_moa is a data gap, so there is no “original indication” text to extract — I’ve stated this plainly rather than inventing one.
Ciprofibrate’s own predicted indications evidence pack flags that rank‑1 (“hyperlipoproteinemia”) is the classic fibrate indication, not a novel hypothesis — I’ve kept that caveat visible rather than glossing over it.
Safety fields are all data gaps → used the mandated fallback sentence.
Not an antineoplastic drug → Cytotoxicity section omitted entirely.
DG001 (Blocking: missing label warnings/contraindications) is carried into Conclusion & Next Steps since it materially limits how far this candidate can proceed.

Ciprofibrate: From Unlicensed Fibrate to Hyperlipoproteinemia

One-Sentence Summary

Ciprofibrate is a fibrate-class lipid-lowering agent with no current UK marketing authorisation on file in this evidence pack. The TxGNN model’s top-ranked prediction is Hyperlipoproteinemia — which, on review of the supporting literature, corresponds to the drug’s long-established classical use rather than a genuinely novel repurposing hypothesis — supported by 0 registered clinical trials and 20 publications, including several historical randomised controlled trials.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (no UK marketing authorisation on file); pharmacologically a fibrate historically used for hyperlipidaemia/hyperlipoproteinaemia
Predicted New Indication	Hyperlipoproteinemia
TxGNN Prediction Score	99.97%
Evidence Level	L2
UK Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed structured mechanism-of-action data is not available for Ciprofibrate in this evidence pack. However, the collected literature and the model’s own rationale consistently describe it as a PPAR-α (peroxisome proliferator-activated receptor alpha) agonist. Activation of PPAR-α upregulates lipoprotein lipase (LPL) and apolipoprotein A-I/A-II expression, which together lower VLDL and triglyceride levels and produce a modest rise in HDL cholesterol.

Importantly, this mechanism maps directly onto the pathophysiology of hyperlipoproteinaemia (Fredrickson types IIa, IIb and IV) — elevated LDL, VLDL and/or triglycerides with reduced HDL. This is precisely the disorder that fibrates as a drug class, including ciprofibrate, were originally developed and extensively studied to treat.

For that reason, this should not be read as a novel repurposing signal: the predicted indication is essentially the drug’s classical, well-characterised use rather than a new therapeutic hypothesis. The clinical value of this evidence pack lies less in “discovering” a new indication and more in confirming that TxGNN correctly recovers a well-known drug–disease relationship — useful as a sanity check on the model, but not something that would independently justify a repurposing programme. Several lower-ranked candidates in this pack (e.g. CETP deficiency, HTGL deficiency, CYP7A1 deficiency, familial hypercholesterolaemia) extend the same PPAR-α/lipid-lowering mechanism into related but less-established territory, and are correspondingly rated L5/Hold pending further evidence; two candidates (prostate fibroma, prostate/brain cancer susceptibility) are flagged in the source data itself as probable knowledge-graph noise with no biological or literature support.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9015467	1996	RCT	Postgraduate Medical Journal	Multicentre, open, parallel-group trial (n=174) comparing ciprofibrate 100 mg/day with sustained-release bezafibrate 400 mg/day in type II hyperlipidaemia; both agents were effective and well tolerated.
8831920	1996	Cohort/open-label	Atherosclerosis	Pooled efficacy/safety data from roughly 3,000 patients on ciprofibrate 100 mg/day across type IIa, IIb and IV hyperlipoproteinaemia; consistent reductions in total cholesterol, triglycerides, apoB and LDL-C.
3994783	1985	RCT (double-blind, comparative)	Atherosclerosis	3-month double-blind comparison of ciprofibrate 100 mg/day vs fenofibrate 300 mg/day; both reduced TC, LDL-C and VLDL-C and increased HDL-C and apoA.
12915663	2003	Clinical mechanistic study	Journal of Clinical Endocrinology and Metabolism	Ciprofibrate 100 mg/day in patients with type IIb hyperlipidaemia reduced atherogenic VLDL subclasses and enhanced HDL-mediated cholesterol efflux.
17414592	2007	Clinical study	American Journal of Therapeutics	Ciprofibrate reduced non-HDL cholesterol and triglycerides while raising HDL-C in patients with Fredrickson type IV dyslipidaemia.
6753860	1982	RCT (double-blind, placebo-controlled)	Atherosclerosis	Randomised, placebo-controlled 12-week trial of ciprofibrate 50/100 mg/day in type II hypercholesterolaemia; dose-dependent lipid lowering, well tolerated.
2289217	1990	Multicentre trial	Clinical Therapeutics	Italian multicentre study of 127 diet-resistant patients with type IIa/IIb hyperlipidaemia on ciprofibrate 100 mg/day for 12 weeks; significant reductions in TC, LDL-C, VLDL-C, TG and apoB, with increases in HDL-C and apoA-I.
11048518	2000	Multicentre cohort	Vnitřní Lékařství	633 patients across 23 Czech centres treated with ciprofibrate (Lipanor) 100 mg/day for 3 months; cholesterol fell 13%, triglycerides fell over 41%, HDL-C rose 15%.
6951582	1982	Dose-response study	Atherosclerosis	Dose-response study (50/100/200 mg/day) in 50 patients with type IIA/IIB/IV hyperlipoproteinaemia; 200 mg/day gave the greatest lipid-lowering effect, normalising LDL-C in types IIA/IIB.
9364979	1997	Comparative study	Thrombosis and Haemostasis	Compared effects of gemfibrozil and ciprofibrate on t-PA, PAI-1 and fibrinogen in hyperlipidaemic patients, exploring haemostatic effects beyond lipid lowering.

UK Market Information

Ciprofibrate is not currently marketed in the UK — this evidence pack records no active MHRA marketing authorisations (0 licences on file). Any repurposing pathway would therefore need to proceed via a new marketing authorisation application or an equivalent regulatory route, not a variation to an existing licence.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Note: This evidence pack flags the absence of label warnings/contraindications and drug-drug interaction data as a blocking gap for formal safety evaluation — see Conclusion and Next Steps below.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link between ciprofibrate’s PPAR-α-mediated lipid-lowering activity and hyperlipoproteinaemia is strong and well supported by decades of published RCTs and cohort studies — but this reflects the drug’s classical, long-established use rather than a novel repurposing opportunity, and no registered clinical trials currently exist for this specific indication in this dataset.

To proceed, the following is needed:

Structured mechanism-of-action data (currently a data gap; sourced provisionally from literature/rationale text only)
SmPC/label warnings and contraindications (flagged as a blocking gap in this evidence pack — required before any formal safety (S1) evaluation can proceed)
Formal drug-drug interaction (DDI) data (current query returned no results)
Clarification of regulatory strategy given zero existing UK marketing authorisations
A reassessment of whether this candidate merits further repurposing investment, given that the top-ranked prediction largely reproduces ciprofibrate’s known pharmacological class use rather than identifying a new therapeutic avenue
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.